UniProtKB/Swiss-Prot P51587: Variant p.Tyr42Cys

Breast cancer type 2 susceptibility protein
Gene: BRCA2
Feedback?

Variant information Variant position:

42 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Tyrosine (Y) to Cysteine (C) at position 42 (Y42C, p.Tyr42Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from large size and aromatic (Y) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

In BC and ovarian cancer; uncertain significance. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs4987046 [ dbSNP | Ensembl ]

Sequence information Variant position:

42 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

3418 The length of the canonical sequence.
Location on the sequence:

ADLGPISLNWFEELSSEAPP Y NSEPAEESEHKNNNYEPNLF The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ADLGPISLNWFEELSSEAPPYNSEPAEESEHKNNNYEPNLF

Mouse                         ADLGPISLNWFEELSSEAPPYNSEPPEESEYKPHGYEPQLF

Rat                           ADLGPISLNWFEELFSEAPPYNTEHPEESEYKPQGHEPQLF

Cat                           ADLGPISLNWFEELCLEAPPYNSEPTEESGYK-ISYEPNLF

Drosophila                    -----------------------------------------

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 3418	Breast cancer type 2 susceptibility protein
Region	37 – 68	Disordered

Literature citations
BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico.
Ruiz-Flores P.; Sinilnikova O.M.; Badzioch M.; Calderon-Garciduenas A.L.; Chopin S.; Fabrice O.; Gonzalez-Guerrero J.F.; Szabo C.; Lenoir G.; Goldgar D.E.; Barrera-Saldana H.A.;
Hum. Mutat. 20:474-475(2002)
Cited for: VARIANTS BC CYS-42; ARG-613; LEU-2118; LEU-2293 AND ARG-2793; VARIANT ILE-3374; One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.
Malander S.; Ridderheim M.; Masbaeck A.; Loman N.; Kristoffersson U.; Olsson H.; Nilbert M.; Borg A.;
Eur. J. Cancer 40:422-428(2004)
Cited for: VARIANT OVARIAN CANCER CYS-42; VARIANTS SER-3063 AND VAL-3412;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.